Drug delivery has seen plenty of acquisitions-but they represent two basic philosophical approaches, represented most recently by Johnson & Johnson's purchase of Alza and Inhale's acquisition of two privately-held firms, Bradford and Shearwater. The basic question: can a service model bring significant returns to a large shareholder base or will Alza's evolution into a product company define the way forward for the industry?